OREGON HEALTH & SCIENCE UNIVERSITY

Support for Congressional action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities, including advocating in support of S.5201/H.R. 7634, the 340B PATIENTS Act of 2024. S.5201/H.R. 7634 clarifies that drug manufacturers are required to offer 340B discount prices to covered entities regardless of the manner or location in which a drug is dispensed, including if a covered entity uses contract pharmacy to dispense 340B drugs to the entitys patients. Communicated support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities, and opposition to limiting the scope of the program and reducing access to drug discounts currently provided under the current program structure.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7634

Support for the use of nonhuman primates in biomedical research, including specific recommendations to US House and Senate appropriators to direct federal agencies such as NIH, Centers for Disease Control and Prevention, and Food and Drug Administration to develop a national plan for nonhuman primate research, especially in regard to nonhuman primate research workforce shortages and supply issues. Provided requested expertise on legislation unrelated to public national primate research, S.4206/H.R. 8164, the Captive Primate Safety Act. Legislation would prohibit private ownership of primates.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 8164

Advocacy for increased Fiscal Year 2025 (FY'25) programmatic appropriations within S.4942/H.R. 9029, the Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act for FY'25, which support OHSU's public missions in health, education and biosciences research. This includes increased investment for the National Institutes of Health (NIH), including funding for cancer research, neurosciences research and the NIH BRAIN Initiative, and national primate research centers; the Agency for Health Care Quality and Research (AHRQ); health professions workforce development and diversity programs (HRSA Title VII and Title VIII and HRSA Centers of Excellence (COE)); HRSA Transforming Pediatrics for Early Childhood Program (TPEC); University Centers for Excellence in Developmental Disabilities (UCEDDs) and Leadership Education in Neurodevelopmental and Related Disabilities (LEND) programs; National Institute for Occupational Safety and Health (NIOSH) and Total Worker Health Program; the Centers for Disease Control and Prevention (CDC) and NIH to conduct public health research into firearm morbidity and mortality prevention; Office of Refugee Resettlement Survivors of Torture program.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 9029

Support for the use of nonhuman primates in biomedical research, including specific recommendations to US House and Senate appropriators to direct federal agencies such as NIH, Centers for Disease Control and Prevention, and Food and Drug Administration to develop a national plan for nonhuman primate research, especially in regard to nonhuman primate research workforce shortages and supply issues. Provided requested expertise on legislation unrelated to public national primate research, S.4206/H.R. 8164, the Captive Primate Safety Act. Legislation would prohibit private ownership of primates.

Client expense: $50,000 · Firm income: —

Matched citations: S.4206

Advocacy for increased Fiscal Year 2025 (FY'25) programmatic appropriations within S.4942/H.R. 9029, the Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act for FY'25, which support OHSU's public missions in health, education and biosciences research. This includes increased investment for the National Institutes of Health (NIH), including funding for cancer research, neurosciences research and the NIH BRAIN Initiative, and national primate research centers; the Agency for Health Care Quality and Research (AHRQ); health professions workforce development and diversity programs (HRSA Title VII and Title VIII and HRSA Centers of Excellence (COE)); HRSA Transforming Pediatrics for Early Childhood Program (TPEC); University Centers for Excellence in Developmental Disabilities (UCEDDs) and Leadership Education in Neurodevelopmental and Related Disabilities (LEND) programs; National Institute for Occupational Safety and Health (NIOSH) and Total Worker Health Program; the Centers for Disease Control and Prevention (CDC) and NIH to conduct public health research into firearm morbidity and mortality prevention; Office of Refugee Resettlement Survivors of Torture program.

Client expense: $50,000 · Firm income: —

Matched citations: S.4942

Support for Congressional action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities, including advocating in support of S.5201/H.R. 7634, the 340B PATIENTS Act of 2024. S.5201/H.R. 7634 clarifies that drug manufacturers are required to offer 340B discount prices to covered entities regardless of the manner or location in which a drug is dispensed, including if a covered entity uses contract pharmacy to dispense 340B drugs to the entitys patients. Communicated support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities, and opposition to limiting the scope of the program and reducing access to drug discounts currently provided under the current program structure.

Client expense: $50,000 · Firm income: —

Matched citations: S.5201

Support for legislation establishing an essential hospital designation in federal law (H.R. 7397) for purposes of reimbursement of services provided under Medicare. Provided clinical expertise and faculty perspective on existing legal barriers to access to reproductive health services, contraception and abortion drugs. Provided perspective of OHSU IT leaders supporting further development of Health Information Exchanges (HIE), including the Trusted Exchange Framework and Common Agreement (TEFCA), urging additional safeguards by HIEs to enhance patient care and protect patient privacy.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7397

Support for Congressional action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities, including advocating in support of S.5201/H.R. 7634, the 340B PATIENTS Act of 2024. S.5201/H.R. 7634 clarifies that drug manufacturers are required to offer 340B discount prices to covered entities regardless of the manner or location in which a drug is dispensed, including if a covered entity uses contract pharmacy to dispense 340B drugs to the entitys patients. Communicated support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities, and opposition to limiting the scope of the program and reducing access to drug discounts currently provided under the current program structure.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7634

Support for the use of nonhuman primates in biomedical research, including specific recommendations to US House and Senate appropriators to direct federal agencies such as NIH, Centers for Disease Control and Prevention, and Food and Drug Administration to develop a national plan for nonhuman primate research, especially in regard to nonhuman primate research workforce shortages and supply issues. Provided requested expertise on legislation unrelated to public national primate research, S.4206/H.R. 8164, the Captive Primate Safety Act. Legislation would prohibit private ownership of primates.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 8164

Advocacy for increased Fiscal Year 2025 (FY'25) programmatic appropriations within S.4942/H.R. 9029, the Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act for FY'25, which support OHSU's public missions in health, education and biosciences research. This includes increased investment for the National Institutes of Health (NIH), including funding for cancer research, neurosciences research and the NIH BRAIN Initiative, and national primate research centers; the Agency for Health Care Quality and Research (AHRQ); health professions workforce development and diversity programs (HRSA Title VII and Title VIII and HRSA Centers of Excellence (COE)); HRSA Transforming Pediatrics for Early Childhood Program (TPEC); University Centers for Excellence in Developmental Disabilities (UCEDDs) and Leadership Education in Neurodevelopmental and Related Disabilities (LEND) programs; National Institute for Occupational Safety and Health (NIOSH) and Total Worker Health Program; the Centers for Disease Control and Prevention (CDC) and NIH to conduct public health research into firearm morbidity and mortality prevention; Office of Refugee Resettlement Survivors of Torture program.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 9029

Support for the use of nonhuman primates in biomedical research, including specific recommendations to US House and Senate appropriators to direct federal agencies such as NIH, Centers for Disease Control and Prevention, and Food and Drug Administration to develop a national plan for nonhuman primate research, especially in regard to nonhuman primate research workforce shortages and supply issues. Provided requested expertise on legislation unrelated to public national primate research, S.4206/H.R. 8164, the Captive Primate Safety Act. Legislation would prohibit private ownership of primates.

Client expense: $50,000 · Firm income: —

Matched citations: S.4206

Advocacy for increased Fiscal Year 2025 (FY'25) programmatic appropriations within S.4942/H.R. 9029, the Departments of Labor, Health and Human Services, Education and Related Agencies Appropriations Act for FY'25, which support OHSU's public missions in health, education and biosciences research. This includes increased investment for the National Institutes of Health (NIH), including funding for cancer research, neurosciences research and the NIH BRAIN Initiative, and national primate research centers; the Agency for Health Care Quality and Research (AHRQ); health professions workforce development and diversity programs (HRSA Title VII and Title VIII and HRSA Centers of Excellence (COE)); HRSA Transforming Pediatrics for Early Childhood Program (TPEC); University Centers for Excellence in Developmental Disabilities (UCEDDs) and Leadership Education in Neurodevelopmental and Related Disabilities (LEND) programs; National Institute for Occupational Safety and Health (NIOSH) and Total Worker Health Program; the Centers for Disease Control and Prevention (CDC) and NIH to conduct public health research into firearm morbidity and mortality prevention; Office of Refugee Resettlement Survivors of Torture program.

Client expense: $50,000 · Firm income: —

Matched citations: S.4942

Support for Congressional action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities, including advocating in support of S.5201/H.R. 7634, the 340B PATIENTS Act of 2024. S.5201/H.R. 7634 clarifies that drug manufacturers are required to offer 340B discount prices to covered entities regardless of the manner or location in which a drug is dispensed, including if a covered entity uses contract pharmacy to dispense 340B drugs to the entitys patients. Communicated support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities, and opposition to limiting the scope of the program and reducing access to drug discounts currently provided under the current program structure.

Client expense: $50,000 · Firm income: —

Matched citations: S.5201

Support for legislation establishing an essential hospital designation in federal law (H.R. 7397) for purposes of reimbursement of services provided under Medicare. Provided clinical expertise and faculty perspective on existing legal barriers to access to reproductive health services, contraception and abortion drugs.

Client expense: $50,000 · Firm income: —

Matched citations: H.R. 7397

Support for waiving the 4% statutory PAYGO sequester that would force cuts to Medicare and other health programs, and addressing cuts resulting from CMS 2023 Medicare Physician Fee Schedule Rule. Medicare support for Medicare Graduate Medical Education, including the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256), bipartisan legislation that would add 14,000 new Medicare-supported graduate medical education (GME) slots. Support for extending CMS's Acute Hospital Care at Home waiver through the Hospital Inpatient Services Modernization Act (H.R. S. 3792/7053), which would extend the waiver for two years beyond the end of the federal public health emergency. Support for the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) which would allow Medicare to reimburse genetic counselors directly and expand access to these services. . . Ensure that individuals eligible for Medicaid and CHIP have stable and comprehensive health coverage that provides affordable access to high-quality care, and closing coverage and care gaps for critical health and behavioral health services. Support for making CHIP funding permanent, and enacting a nationwide standard to ensure12-month continuous eligibility to children enrolled in CHIP and/or Medicaid.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 2144

Support for waiving the 4% statutory PAYGO sequester that would force cuts to Medicare and other health programs, and addressing cuts resulting from CMS 2023 Medicare Physician Fee Schedule Rule. Medicare support for Medicare Graduate Medical Education, including the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256), bipartisan legislation that would add 14,000 new Medicare-supported graduate medical education (GME) slots. Support for extending CMS's Acute Hospital Care at Home waiver through the Hospital Inpatient Services Modernization Act (H.R. S. 3792/7053), which would extend the waiver for two years beyond the end of the federal public health emergency. Support for the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) which would allow Medicare to reimburse genetic counselors directly and expand access to these services. . . Ensure that individuals eligible for Medicaid and CHIP have stable and comprehensive health coverage that provides affordable access to high-quality care, and closing coverage and care gaps for critical health and behavioral health services. Support for making CHIP funding permanent, and enacting a nationwide standard to ensure12-month continuous eligibility to children enrolled in CHIP and/or Medicaid.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 2256

Support for extending the COVID-19 Public Health Emergency beyond January 16, 2022. Support for establishing a public health emergency for Respiratory Syncytial Virus Infection (RSV) to ensure hospital and childrens hospital capacity to serve pediatric and adult patients during surge in cases. Support for extension beyond the end of the public health emergency of temporary flexibilities to allow providers to be reimbursed for telehealth at parity with in-person services and make it easier for telehealth to be used by both providers and beneficiaries, including the Advancing Telehealth Beyond COVID-19 Act (H.R. 4040) to extend through December 2024 key telehealth waivers implemented during the COVID-19 pandemic. Discussion of proposed policies to designate certain hospitals as Essential Hospitals and/or Metropolitan Anchor Hospitals to better target resources to those hospitals that ensure equitable access to care and public health, and train health care professionals to meet community demand for physicians, nurses, and other caregivers. Discussion of policies for ensuring continuous access to reproductive health services. Discussion of policies related to behavioral health, including proposals developed by the Senate Finance Committee.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 4040

Inclusion of an emergency fund for academic health centers in COVID relief legislation, support for the unique higher education needs of academic health centers in training health care professionals. Support for the Future Advancement of Academic Nursing (FAAN) Act (S.246/H.R. 851), which would invest $1 billion into schools of nursing to ensure nursing education pathways remain strong during current and future public health challenges, such as the COVID-19 pandemic.

Client expense: $70,000 · Firm income: —

Matched citations: H.R. 851

Support for waiving the 4% statutory PAYGO sequester that would force cuts to Medicare and other health programs, and addressing cuts resulting from CMS 2023 Medicare Physician Fee Schedule Rule. Medicare support for Medicare Graduate Medical Education, including the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256), bipartisan legislation that would add 14,000 new Medicare-supported graduate medical education (GME) slots. Support for extending CMS's Acute Hospital Care at Home waiver through the Hospital Inpatient Services Modernization Act (H.R. S. 3792/7053), which would extend the waiver for two years beyond the end of the federal public health emergency. Support for the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) which would allow Medicare to reimburse genetic counselors directly and expand access to these services. . . Ensure that individuals eligible for Medicaid and CHIP have stable and comprehensive health coverage that provides affordable access to high-quality care, and closing coverage and care gaps for critical health and behavioral health services. Support for making CHIP funding permanent, and enacting a nationwide standard to ensure12-month continuous eligibility to children enrolled in CHIP and/or Medicaid.

Client expense: $70,000 · Firm income: —

Matched citations: S. 1450

Inclusion of an emergency fund for academic health centers in COVID relief legislation, support for the unique higher education needs of academic health centers in training health care professionals. Support for the Future Advancement of Academic Nursing (FAAN) Act (S.246/H.R. 851), which would invest $1 billion into schools of nursing to ensure nursing education pathways remain strong during current and future public health challenges, such as the COVID-19 pandemic.

Client expense: $70,000 · Firm income: —

Matched citations: S.246

Support for waiving the 4% statutory PAYGO sequester that would force cuts to Medicare and other health programs, and addressing cuts resulting from CMS 2023 Medicare Physician Fee Schedule Rule. Medicare support for Medicare Graduate Medical Education, including the Resident Physician Shortage Reduction Act (S. 834/H.R. 2256), bipartisan legislation that would add 14,000 new Medicare-supported graduate medical education (GME) slots. Support for extending CMS's Acute Hospital Care at Home waiver through the Hospital Inpatient Services Modernization Act (H.R. S. 3792/7053), which would extend the waiver for two years beyond the end of the federal public health emergency. Support for the Access to Genetic Counselor Services Act (S. 1450/H.R. 2144) which would allow Medicare to reimburse genetic counselors directly and expand access to these services. . . Ensure that individuals eligible for Medicaid and CHIP have stable and comprehensive health coverage that provides affordable access to high-quality care, and closing coverage and care gaps for critical health and behavioral health services. Support for making CHIP funding permanent, and enacting a nationwide standard to ensure12-month continuous eligibility to children enrolled in CHIP and/or Medicaid.

Client expense: $70,000 · Firm income: —

Matched citations: S. 3792